PT-141 enhances arousal and sexual response through a separate neurological pathway
Injectables currently have stronger trial data and more predictable effects
GH reports research grants from the Netherlands Organization for Scientific Research (vidi 016.156.445), CardioVascular Research Initiative, European Union and the Klinkerpad fonds, institutional research support from Aegerion, Amgen, AstraZeneca, Eli Lilly, Genzyme, Ionis, Kowa, Pfizer, Regeneron, Roche, Sanofi, and The Medicines Company
Emerging peptides under study may suppress appetite via brain pathways that avoid the gastric slowing responsible for common GI side effects of current GLP-1 drugs
This could mean that we may see generics for popular drugs like semaglutide and tirzepatide in the future, further expanding treatment options for patients
If youre interested in learning more about how semaglutide GLP-1 can be part of your weight loss journey, visit Noor Medical Spa